Advertisement
Canada markets open in 8 hours 55 minutes
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7320
    -0.0000 (-0.00%)
     
  • CRUDE OIL

    83.44
    +0.08 (+0.10%)
     
  • Bitcoin CAD

    91,130.22
    +354.80 (+0.39%)
     
  • CMC Crypto 200

    1,436.37
    +21.61 (+1.53%)
     
  • GOLD FUTURES

    2,340.70
    -1.40 (-0.06%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ futures

    17,728.25
    +121.50 (+0.69%)
     
  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    38,367.65
    +815.49 (+2.17%)
     
  • CAD/EUR

    0.6832
    -0.0004 (-0.06%)
     

Five Star Equities Issues New Research Reports on AMBA, CIMT, RGDX and TSN

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

Ambarella Inc. (NASDAQ:AMBA - News) shares declined 10.83 percent to close at $13.42 a share Monday. The stock traded between $13.25 and $15.40 on volume of 3.33 million shares traded. The company will hold its second quarter fiscal 2014 conference call on Thursday, Sept. 5, 2013, at 2pm Pacific Time. Shares of Ambarella have gained approximately 20.0 percent year-to-date.

Get more information on Ambarella and free access to the in-depth equity report at:
www.FiveStarEquities.com/AMBA

Cimatron Ltd. (NASDAQ:CIMT - News) shares surged 19.03 percent to close at $7.38 a share Monday. The stock traded between $6.20 and $7.50 on volume of 1.67 million shares traded. The company reported record revenues of $11.0 million for the second quarter of 2013. Shares of Cimatron have gained approximately 40.0 percent year-to-date.

ADVERTISEMENT

Get more information on Cimatron and free access to the in-depth equity report at:
www.FiveStarEquities.com/CIMT

Response Genetics, Inc. (NASDAQ:RGDX - News) shares soared 27.13 percent to close at $2.39 a share Monday. The stock traded between $2.20 and $2.93 on volume of 1.85 million shares traded. The company announced it has acquired all of the key assets of Pathwork Diagnostics, including its FDA-cleared Medicare-reimbursed test. Shares of Response Genetics have gained approximately 72.0 percent year-to-date.

Get more information on Response Genetics and free access to the in-depth equity report at:
www.FiveStarEquities.com/RGDX

Tyson Foods, Inc. (NYSE:TSN - News) dropped 7.34 percent to close at $29.17 a share Monday. The stock traded between $29.12 and $30.89 on volume of 11.30 million shares traded. Bank of America-Merrill Lynch has recently downgraded the company’s rating to "neutral" from "buy". Shares of Tyson Foods have gained approximately 50.0 percent year-to-date.

Get more information on Tyson Foods and free access to the in-depth equity report at:
www.FiveStarEquities.com/TSN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com